The BRAFV600E mutation, which renders BRAF constitutively active with a 500-fold increase in kinase activity compared to wild-type BRAF [5], represents approximately 90% of all BRAF mutations observed in colon cancer patients. Here, BRAF is linked to malignant colon neoplasm.